Literature DB >> 24900760

Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases.

Qingqing Meng1, Feng Li1, Sheng Jiang2, Zheng Li1.   

Abstract

We report the design, synthesis, and biological evaluation of a (64)Cu-labeled histone deacetylase (HDAC) imaging probe, which was obtained by introduction of metal chelator through click reaction of HDAC inhibitor CUDC-101 and then radiolabeled with (64)Cu. The resulting (64)Cu-labeled compound 7 ([(64)Cu]7) was identified as a positron emission tomography (PET) imaging probe to noninvasively visualize HDAC expression in vivo. Cell based competitive assay established the specific binding of [(64)Cu]7 to HDACs. Biodistribution and small-animal microPET/CT studies further showed that [(64)Cu]7 had high tumor to background ratio in the MDA-MB-231 xenograft model, a triple-negative breast cancer with high expression of HDACs. To our knowledge, [(64)Cu]7 thus represents the first (64)Cu-labeled PET HDAC imaging probe, which exhibits nanomolar range binding affinity and capability to imaging HDAC expression in triple-negative breast cancer in vivo.

Entities:  

Keywords:  64Cu radiolabeling; CUDC-101; PET imaging probe; histone deacetylases inhibitors; triple-negative breast cancer

Year:  2013        PMID: 24900760      PMCID: PMC4027442          DOI: 10.1021/ml400191z

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

Review 1.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

2.  CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.

Authors:  Cheng-Jung Lai; Rudi Bao; Xu Tao; Jing Wang; Ruzanna Atoyan; Hui Qu; Da-Gong Wang; Ling Yin; Maria Samson; Jeffrey Forrester; Brian Zifcak; Guang-Xin Xu; Steven DellaRocca; Hai-Xiao Zhai; Xiong Cai; William E Munger; Mitchell Keegan; Carmen V Pepicelli; Changgeng Qian
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

Review 3.  Imaging cellular receptors in breast cancers: an overview.

Authors:  Thillai V Sekar; Aradhana Dhanabalan; Ramasamy Paulmurugan
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

4.  Crystal structure of a bacterial class 2 histone deacetylase homologue.

Authors:  Tine Kragh Nielsen; Christian Hildmann; Achim Dickmanns; Andreas Schwienhorst; Ralf Ficner
Journal:  J Mol Biol       Date:  2005-10-07       Impact factor: 5.469

Review 5.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

6.  Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.

Authors:  Weiwei Feng; Zhen Lu; Robert Z Luo; Xiaohong Zhang; Edward Seto; Warren S-L Liao; Yinhua Yu
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

7.  Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.

Authors:  Wilko Weichert; Annika Röske; Silvia Niesporek; Aurelia Noske; Ann-Christin Buckendahl; Manfred Dietel; Volker Gekeler; Markus Boehm; Thomas Beckers; Carsten Denkert
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

8.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

Authors:  Ivan V Gregoretti; Yun-Mi Lee; Holly V Goodson
Journal:  J Mol Biol       Date:  2004-04-16       Impact factor: 5.469

9.  Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Authors:  Chandra R Tate; Lyndsay V Rhodes; H Chris Segar; Jennifer L Driver; F Nell Pounder; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Breast Cancer Res       Date:  2012-05-21       Impact factor: 6.466

10.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Authors:  W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  8 in total

1.  Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Yi-An Chen; Cheng-Hsiu Lu; Chien-Chih Ke; Sain-Jhih Chiu; Chi-Wei Chang; Bang-Hung Yang; Juri G Gelovani; Ren-Shyan Liu
Journal:  Int J Mol Sci       Date:  2021-08-11       Impact factor: 5.923

Review 2.  Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer.

Authors:  Hanyi Fang; Alessandra Cavaliere; Ziqi Li; Yiyun Huang; Bernadette Marquez-Nostra
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

Review 3.  The application of click chemistry in the synthesis of agents with anticancer activity.

Authors:  Nan Ma; Ying Wang; Bing-Xin Zhao; Wen-Cai Ye; Sheng Jiang
Journal:  Drug Des Devel Ther       Date:  2015-03-12       Impact factor: 4.162

Review 4.  Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT.

Authors:  Brian P Rempel; Eric W Price; Christopher P Phenix
Journal:  Mol Imaging       Date:  2017 Jan-Dec       Impact factor: 4.488

Review 5.  HDAC Inhibitors: Innovative Strategies for Their Design and Applications.

Authors:  Mateusz Daśko; Beatriz de Pascual-Teresa; Irene Ortín; Ana Ramos
Journal:  Molecules       Date:  2022-01-21       Impact factor: 4.411

6.  Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain.

Authors:  Robin Bonomi; Uday Mukhopadhyay; Aleksandr Shavrin; Hsien-Hsien Yeh; Anjoy Majhi; Sajeewa W Dewage; Amer Najjar; Xin Lu; G Andrés Cisneros; William P Tong; Mian M Alauddin; Ren-Shuan Liu; Thomas J Mangner; Nashaat Turkman; Juri G Gelovani
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

Review 7.  PET Imaging of Epigenetic Influences on Alzheimer's Disease.

Authors:  Paul J Couto; Richard M Millis
Journal:  Int J Alzheimers Dis       Date:  2015-10-22

Review 8.  Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases.

Authors:  Tetsuro Tago; Jun Toyohara
Journal:  Molecules       Date:  2018-01-31       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.